05:07 PM EDT, 09/04/2025 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) said late Thursday the US Food and Drug Administration approved various dosages of risperidone extended-release injectable suspension indicated for the treatments of schizophrenia and bipolar I disorder.

The product is eligible for 180-day exclusivity under the FDA's Competitive Generic Therapy designation, the company said.

The launch of the product is planned for Q4, according to a statement.